Pilot Study on Proteomics of Erythrocyte Proteins in Patients With COPD Based on TMT Technology

Completed

• Conditions: Protein; Disease
• Interventions: Other: no intervention

• Registration Number: NCT05376618
• Lead Sponsor: Zhujiang Hospital

Brief Summary

Chronic obstructive pulmonary disease (COPD), a common and complex disease characterized by persistent airflow limitation, is a leading cause of mortality worldwide. COPD and its comorbidity are associated with hypoxia condition. Further investigations on the cellular and molecular aspects of hypoxia in COPD should help to reveal the mechanisms underlying the development of this disease. Dysfunction of the erythrocyte, a main medium to transport oxygen through the blood, contributes to the prognosis and severity of COPD through hypoxia. It is proposed that dysregulated proteins in erythrocytes that impair oxygen transport may be involved in the development of COPD. However, a comprehensive study on altered proteins of erythrocytes in COPD is still lacking. Proteomics techniques and protein chip techniques provide a high throughput screening method to figure out characteristic inflammatory or metabolic markers of diseases. Therefore, this study is to evaluate the clinical significance of differential erythrocyte proteins in the course of COPD disease.

Detailed Description

Not available

Study Timeline

• Status Verified: 2021-07
• Study Start: 2021-07-15
• Study First Submitted: 2022-05-11
• Study First Submitted QC: 2022-05-11
• Study First Posted: 2022-05-17
• Primary Completion: 2022-07-15
• Study Completion: 2022-07-15
• Last Update Submitted: 2024-03-12
• Last Update Posted: 2024-03-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

1. Age from 40 to 80 years old; gender is not limited. 2. Stable COPD 3. Sign the informed consent with the willingness of obeying the protocol. -

Exclusion Criteria

1. Subjects with known other chronic respiratory diseases except for COPD (such as asthma, tuberculosis, bronchiectasis, interstitial lung disease, occupational lung diseases, sarcoidosis, lung cancer, et al); 2. Subjects had been accepted lung lobectomy or transplantation; 3. Subjects be ill with severe, or uncontrolled systemic diseases other than COPD (such as psychiatry diseases, chronic liver diseases, heart failure, auto-immunity diseases, chronic renal diseases, et al ); 4. Alcoholism, drug or solvents addition; 5. Acute exacerbation COPD patients (AECOPD) -

2. control group Inclusion criteria

   1. Age from 40 to 80 years old; gender is not limited.
   2. Sign the informed consent with the willingness of obeying the protocol. - Exclusion criteria
   <!-- -->
   1. Subjects with known other chronic respiratory diseases (such as COPD, asthma, tuberculosis, bronchiectasis, interstitial lung disease, occupational lung diseases, sarcoidosis, lung cancer, et al);
   2. Subjects had been accepted lung lobectomy or transplantation;
   3. Subjects be ill with severe, or uncontrolled systemic diseases other than COPD (such as psychiatry diseases, chronic liver diseases, heart failure, auto-immunity diseases, chronic renal diseases, et al );
   4. Alcoholism, drug or solvents addition;

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Healthy	no intervention	-
stable COPD	no intervention	-

Primary Outcome Measures

Name	Time	Method
Protein biomarkers in erythrocyte predicting rapid decline of lung function	2021-7-15 to 2022-7-15	The study is to identify the biomarkers and make sure which is associated with rapid decline of lung function. The study will include a total of 30 study subjects.

Trial Locations

Locations (1)

Zhujiang Hospital,Southern Medical Universtiy; 🇨🇳 Guangzhou, Guangdong, China